All In Biotech

Drug Trial Radar · NCT04263363

Applying Best Clinical Practices to Patients at High Risk of Respiratory Complications

A Prospective Digital Quality Improvement Project to Apply Best Clinical Practices to Patients at High Risk of Respiratory Complications

Last checked: Nov 19, 2026Latest source record: Jul 29, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

12,248

Actual

Start

Feb 18, 2022

Primary completion

May 7, 2024

Study completion May 7, 2025

Sponsor

Lead sponsor
University of California, Los AngelesAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Merck Sharp & Dohme LLC
First posted
Feb 10, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Prevention
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to: 1. Perform a retrospective analysis on data contained in the UCLA Perioperative Data Warehouse on the incidence of respiratory dysfunction in the post-operative care unit (PACU) before and after the introduction of sugammadex into clinical practice. 2. Develop and implement a clinical best practice pathway designed to prevent postoperative respiratory complications in higher risk patients (such as those with OSA or preexisting respiratory disease) using education and clinical decision support in patients.

Conditions

  • Respiratory Complication
  • Obstructive Sleep Apnea

Interventions

  • Sugammadex 100 MG/ML [Bridion]Drug

    Sugammadex administered to patients within the clinical best practice pathway.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Time to "Fitness for Discharge" From the Recovery RoomTime frame: One year prior to study intervention to one year following implementation of study intervention
  2. Incidence of Hypoxemia in the PACU (Oxygen Saturation Below 90%)Time frame: One year prior to study intervention to one year following implementation of study intervention

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Ronald Reagan UCLA Medical Center

    Los Angeles, California

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.